Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. I...

Full description

Bibliographic Details
Main Authors: Daniel Leung, Xiaofeng Mu, Jaime S. Rosa Duque, Samuel M. S. Cheng, Manni Wang, Wenyue Zhang, Yanmei Zhang, Issan Y. S. Tam, Toby S. S. Lee, Jennifer H. Y. Lam, Sau Man Chan, Cheuk Hei Cheang, Yuet Chung, Howard H. W. Wong, Amos M. T. Lee, Wing Yan Li, Sara Chaothai, Leo C. H. Tsang, Gilbert T. Chua, Kai-Ning Cheong, Elaine Y. L. Au, Janette S. Y. Kwok, Koon Wing Chan, Patrick C. Y. Chong, Pamela P. W. Lee, Marco H. K. Ho, Tsz Leung Lee, Wenwei Tu, Malik Peiris, Yu Lung Lau
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
BNT162b2
CoronaVac
COVID-19
inborn errors of immunity
vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.982155/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.982155/full

Similar Items